Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations (Q58023828)

1

0 references

Baerbel Spies-Weisshart

2

0 references

Anne Klink

3

0 references

Lars-Olof Muegge

4

0 references

Hans-Joerg Fricke

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

5

0 references

publication date

21 July 2010

0 references

published in

Annals of Hematology

0 references

volume

90

0 references

page(s)

473-475

0 references

issue

4

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Potential role of sorafenib in the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9

Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1027-9